Ovid Therapeutics Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 44

Employees
  • Stock Symbol
  • OVID

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $2.42

  • (As of Wednesday Closing)

Ovid Therapeutics General Information

Description

Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life.

Contact Information

Website
www.ovidrx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 1460 Broadway
  • Suite 15021
  • New York, NY 10036
  • United States
+1 (646) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ovid Therapeutics Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.42 $2.50 $1.41 - $3.55 $176M 70.5M 88K -$0.99

Ovid Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (6,827) 16,796 59,669 160,530
Revenue 1,456 208,383 12,617 0
EBITDA (68,015) 124,400 (80,729) (60,206)
Net Income (68,664) 122,835 (81,036) (60,461)
Total Assets 165,032 194,545 75,926 80,844
Total Debt 16,249
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ovid Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ovid Therapeutics‘s full profile, request access.

Request a free trial

Ovid Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Ovid Therapeutics‘s full profile, request access.

Request a free trial

Ovid Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines fo
Drug Discovery
New York, NY
44 As of 2022
00000
000000000 00000

000000

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e
0000 000000000
San Carlos, CA
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00

000000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullam
0000 000000000
New York, NY
00 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ovid Therapeutics Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CuraSen Venture Capital-Backed San Carlos, CA 00 000.00 00000000000 000.00
000000000 00000000 Formerly VC-backed New York, NY 00 000.00 00000000 000.00
000000000000 Venture Capital-Backed Clarksville, MD 0 00.000 00000000000
0000000 0000000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
00000000 000000000 Corporation Coral Gables, FL 00 000.00 00000000 000.00
You’re viewing 5 of 14 competitors. Get the full list »

Ovid Therapeutics Patents

Ovid Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020405060-A1 Gaboxadol for therapeutic treatment of 1p36 deletion syndrome Pending 18-Dec-2019 0000000000
CA-3164635-A1 Gaboxadol for therapeutic treatment of 1p36 deletion syndrome Pending 18-Dec-2019 0000000000
EP-4051272-A1 Gaboxadol for therapeutic treatment of 1p36 deletion syndrome Pending 18-Dec-2019 0000000000
EP-4051272-A4 Gaboxadol for therapeutic treatment of 1p36 deletion syndrome Pending 18-Dec-2019 0000000000
US-11364228-B2 Gaboxadol for therapeutic treatment of 1p36 deletion syndrome Active 18-Dec-2019 A61K31/437 00
To view Ovid Therapeutics’s complete patent history, request access »

Ovid Therapeutics Executive Team (15)

Name Title Board Seat Contact Info
Jeremy Levin Ph.D Chief Executive Officer & Chairman
Suzanne Wakamoto Senior Vice President, Human Resources
Jeffrey Rona Chief Business & Financial Officer
Jason Tardio Chief Commercial Officer
Thomas Perone JD General Counsel, Legal & Secretary, Administration
You’re viewing 5 of 15 executive team members. Get the full list »

Ovid Therapeutics Board Members (8)

Name Representing Role Since
Barbara Duncan Ovid Therapeutics Board Member 000 0000
Bart Friedman JD Self Board Member 000 0000
Jeremy Levin Ph.D Ovid Therapeutics Chief Executive Officer & Chairman 000 0000
Karen Bernstein Ph.D Self Board Member 000 0000
Kevin Fitzgerald Ovid Therapeutics Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Ovid Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ovid Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 06-Sep-2022 00000 0000 000 Biotechnology 000000 00
To view Ovid Therapeutics’s complete investments history, request access »

Ovid Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 12, 2019

29.96 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,042

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 947

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 427

Rank

00.00

Percentile

To view Ovid Therapeutics’s complete esg history, request access »